相关实验视频
Updated: Sep 14, 2025

06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
343
无机纳米材料作为眼睛新血管化的有希望的治疗剂:进展和前景
Yizhuo Geng1,2, Jingjuan Zhang1, Shiyu Song1,2
1Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Materials today. Bio
|July 21, 2025
概括
新型无机纳米材料为治疗眼部病理性新血管化提供了有希望的替代方案,解决了当前抗血管内皮生长因子 (VEGF) 疗法的局限性. 这些材料显示出增强眼内向治疗和改善视力保护的潜力.
科学领域:
- 眼科医生 眼科 眼科
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
背景情况:
- 眼部病理性新血管化导致显著的视力丧失,并且经常用抗血管内皮生长因子 (VEGF) 药物治疗.
- 目前的抗VEGF疗法存在局限性,包括严重的并发症和副作用,需要新的治疗策略.
研究的目的:
- 审查使用无机纳米材料治疗眼部新血管化的最新进展.
- 讨论当前治疗策略的局限性,并强调无机纳米材料的潜力.
主要方法:
- 总结了最近对无机纳米材料 (金属和非金属) 的研究,用于眼部疾病中的抗血管生成.
- 审查了这些纳米材料在眼部新血管化治疗中的特性,优势和具体应用.
主要成果:
- 无机纳米材料具有优良的物理和化学性能,适合功能修改和与其他纳米载体集成.
- 这些材料显示了眼内向治疗的潜力,并在治疗眼部新血管化的过程中增强了治疗效果.
结论:
- 无机纳米材料在开发用于眼部新血管化的新疗法方面是一个有前途的前沿.
- 这些材料的进一步开发可能会导致对危及视力的眼睛疾病的改善治疗方法.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Open Angle Glaucoma: Treatment
577
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
577

